Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2019

View Archived Issues

Hormonal obesity promoter identified

Drugs blocking "hugs" could fight fibrosis

Kinases and chemo

Results from dose-selection trial of H56:IC31 vaccine candidate in tuberculosis-endemic populations

Fever directs traffic to strengthen immune response

Blincyto approved for expanded indication in Europe

I-Mab receives FDA IND clearance for phase I study of TJD-5

Rocket Pharmaceuticals announces FDA clearance of IND for RPA-501 gene therapy

Voclosporin ophthalmic solution demonstrates statistically superior efficacy versus Restasis

Margetuximab plus pembrolizumab shows promising activity in HER2+ (IHC3+) gastric carcinoma

Ramucirumab plus nivolumab shows promising antitumor activity in phase I/II NivoRam study

KemPharm presents phase I data for KP-415

Daiichi Sankyo presents phase I data for DS-8895a in patients with solid tumors

SM-88 appears safe and active in phase II trial in metastatic pancreatic adenocarcinoma

Sorrento reports phase Ib interim analysis with resiniferatoxin in knee osteoarthritis pain

Esteve Pharmaceuticals presents new analgesics

AstraZeneca divulges new SERDs

Phase III study of NexoBrid meets primary and secondary endpoints

Bio-Thera begins phase III study of tocilizumab biosimilar BAT-1806

Beijing Foreland Pharma identifies lysophospholipid S1P1 receptor ligands

Ultragenyx reports long-term extension study results for UX-007 in LC-FAOD

New PRMT5 inhibitors presented by Bayer

Shenzhen Targetrx Biotechnology patents EGFR double-mutant inhibitors

PROLONG study of OBE-022 in preterm labor advances into part B following successful part A

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...